Find a Clinical Trial

With over 70 clinical trials across the globe, Karyopharm is committed to developing novel treatment options to patients in need. Search here for ongoing clinical trials evaluating Karyopharm’s investigational medicines.

Karyopharm-Sponsored Trials Investigator-Sponsored Trials

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Newly Diagnosed or Recurrent Advanced Melanoma

Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to initial checkpoint inhibitor (CPI) therapy in Arm A and Acquired resistance to initial CPI therapy in Arm B. Participants who have disease progression (PD) after discontinuation of CPIs, especially in neoadjuvant or adjuvant therapy, will be considered to have acquired resistance in this study. Participants will receive study treatment (Selinexor and Pembrolizumab) until PD, intolerable toxicity or withdrawal from the study, whichever occurs first.
Primary Condition
Melanoma
Sponsor
Karyopharm Therapeutics Inc
Status
Recruiting
Drug
Selinexor
Phase
Phase 2
Age Group
18 Years+
Primary Condition
Melanoma

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.
Primary Condition
Melanoma
Sponsor
Kari Kendra
Status
Unknown status
Drug
selinexor
Phase
Phase 1
Age Group
18 Years+
Primary Condition
Melanoma